145 related articles for article (PubMed ID: 34172630)
1. Two-Year Experience With Latanoprostene Bunod in Clinical Practice.
Radell JE; Sharma HK; Auyeung KL; Paul ME; Gagliuso DJ; Chadha N; Tsai JC; Serle JB
J Glaucoma; 2021 Sep; 30(9):776-780. PubMed ID: 34172630
[TBL] [Abstract][Full Text] [Related]
2. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
Fingeret M; Gaddie IB; Bloomenstein M
Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
[TBL] [Abstract][Full Text] [Related]
3. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL;
Br J Ophthalmol; 2015 Jun; 99(6):738-45. PubMed ID: 25488946
[TBL] [Abstract][Full Text] [Related]
4. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.
Weinreb RN; Liebmann JM; Martin KR; Kaufman PL; Vittitow JL
J Glaucoma; 2018 Jan; 27(1):7-15. PubMed ID: 29194198
[TBL] [Abstract][Full Text] [Related]
5. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
6. Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.
Mehta AA; Kanu LN; Sood-Mendiratta S; Quinones R; Hawkins A; Lehrer RA; Malhotra K; Papas R; Hillman D; Wilensky JT; Aref AA; Vajaranant TS; Edward DP
Eur J Ophthalmol; 2022 Jan; 32(1):322-326. PubMed ID: 33653172
[TBL] [Abstract][Full Text] [Related]
7. Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
Kawase K; Vittitow JL; Weinreb RN; Araie M;
Adv Ther; 2016 Sep; 33(9):1612-27. PubMed ID: 27457469
[TBL] [Abstract][Full Text] [Related]
8. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.
Harasymowycz P; Royer C; Cui AX; Barbeau M; Jobin-Gervais K; Mathurin K; Lachaine J; Beauchemin C
Br J Ophthalmol; 2022 May; 106(5):640-647. PubMed ID: 33397657
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.
Medeiros FA; Martin KR; Peace J; Scassellati Sforzolini B; Vittitow JL; Weinreb RN
Am J Ophthalmol; 2016 Aug; 168():250-259. PubMed ID: 27210275
[TBL] [Abstract][Full Text] [Related]
10. Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Chart Review.
Okeke CO; Cothran NL; Brinkley DA; Rahmatnejad K; Rodiño FJ; Deom JE
Clin Ophthalmol; 2024; 18():409-422. PubMed ID: 38348139
[TBL] [Abstract][Full Text] [Related]
11. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.
Cavet ME; DeCory HH
J Ocul Pharmacol Ther; 2018; 34(1-2):52-60. PubMed ID: 28783422
[TBL] [Abstract][Full Text] [Related]
12. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
Hoy SM
Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
[TBL] [Abstract][Full Text] [Related]
13. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
Kaufman PL
Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects.
Araie M; Sforzolini BS; Vittitow J; Weinreb RN
Adv Ther; 2015 Nov; 32(11):1128-39. PubMed ID: 26563323
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma.
Wang Y; Liao Y; Nie X
Clinics (Sao Paulo); 2020; 75():e1874. PubMed ID: 33263632
[TBL] [Abstract][Full Text] [Related]
16. Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma.
Zhou B; Bekerman VP; Khouri AS
J Curr Glaucoma Pract; 2022; 16(3):166-169. PubMed ID: 36793262
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of latanoprost and latanoprostene bunod on intraocular pressure and pupil size in ophthalmologically normal Beagle dogs.
Desai SJ; Pumphrey SA; Koethe B
Vet Ophthalmol; 2022 Jul; 25(4):282-290. PubMed ID: 35247289
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.
Liu JHK; Slight JR; Vittitow JL; Scassellati Sforzolini B; Weinreb RN
Am J Ophthalmol; 2016 Sep; 169():249-257. PubMed ID: 27457257
[TBL] [Abstract][Full Text] [Related]
19. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
Mehran NA; Sinha S; Razeghinejad R
Eye (Lond); 2020 Jan; 34(1):72-88. PubMed ID: 31695162
[TBL] [Abstract][Full Text] [Related]
20. Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis.
Lo TC; Chen YY; Hung MC; Chou P
J Clin Med; 2022 Jul; 11(15):. PubMed ID: 35893417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
